XNASSLRX
Market cap2mUSD
Dec 23, Last price
1.57USD
1D
1.29%
1Q
1.29%
Jan 2017
-99.99%
IPO
-100.00%
Name
Salarius Pharmaceuticals Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
157.52%
Rev. gr., 5y
26.48%
Revenues
0k
Net income
0k
P
CFO
-13m
L-26.99%
Earnings
Mar 20, 2025
Profile
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
| Income | ||||||||||
Revenues | 1,840 -64.84% | |||||||||
Cost of revenue | 10 | 22,982 | 14,672 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (10) | (22,982) | (12,832) | |||||||
NOPBT Margin | ||||||||||
Operating Taxes | (233) | (64) | ||||||||
Tax Rate | ||||||||||
NOPAT | (10) | (22,749) | (12,768) | |||||||
Net income | (31,375) 146.96% | (12,704) 79.02% | ||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 6,921 | 1,987 | 27,288 | |||||||
BB yield | -40.77% | -7.64% | -16.64% | |||||||
| Debt | ||||||||||
Debt current | 290 | |||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | 1,408 | 568 | ||||||||
Net debt | (5,610) | (12,106) | (30,825) | |||||||
| Cash flow | ||||||||||
Cash from operating activities | (12,846) | (17,595) | (10,200) | |||||||
CAPEX | (3) | (1,500) | ||||||||
Cash from investing activities | (1,500) | |||||||||
Cash from financing activities | 6,640 | 1,987 | 28,296 | |||||||
FCF | (10) | (22,741) | (10,372) | |||||||
| Balance | ||||||||||
Cash | 5,900 | 12,106 | 29,214 | |||||||
Long term investments | 1,610 | |||||||||
Excess cash | 5,900 | 12,106 | 30,733 | |||||||
Stockholders' equity | (76,347) | (63,805) | (32,193) | |||||||
Invested Capital | 81,924 | 74,190 | 70,916 | |||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | 3,265 | 2,125 | 1,655 | |||||||
Price | 5.20 -57.52% | 12.24 -87.65% | 99.12 -45.54% | |||||||
Market cap | 16,976 -34.72% | 26,004 -84.14% | 164,008 44.61% | |||||||
EV | 11,366 | 13,898 | 133,183 | |||||||
EBITDA | (22,975) | (12,813) | ||||||||
EV/EBITDA | ||||||||||
Interest | 233 | |||||||||
Interest/NOPBT | ||||||||||